Literature DB >> 8437236

Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles.

H Sakai1, R Shibata, J Sakuragi, S Sakuragi, M Kawamura, A Adachi.   

Abstract

A highly sensitive single-round infection assay using a bacterial chloramphenicol acetyltransferase was developed to analyze an early stage of human immunodeficiency virus type 1 replication. By a combination of transfection and single-round infection assay, a virus with a vif mutation, depending on host cells from which the virus was derived, was demonstrated to be defective at the early phase of infection cycle. Analysis of viral proteins synthesized in cells indicated that incorporation of the Env surface protein into virions of the vif mutant, again in a cell-dependent way, was greatly restricted. Taken together, it is concluded that the Vif protein acts through modulation of the Env protein in the virions, directly or indirectly, to enhance viral infectivity in a certain cell type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437236      PMCID: PMC237539     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

Review 1.  Functions of the auxiliary gene products of the human immunodeficiency virus type 1.

Authors:  B R Cullen; W C Greene
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

2.  Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.

Authors:  R Shibata; M Kawamura; H Sakai; M Hayami; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Generation and characterization of the human immunodeficiency virus type 1 mutants.

Authors:  A Adachi; N Ono; H Sakai; K Ogawa; R Shibata; T Kiyomasu; H Masuike; S Ueda
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

4.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Mutational analysis of the human immunodeficiency virus vpr open reading frame.

Authors:  K Ogawa; R Shibata; T Kiyomasu; I Higuchi; Y Kishida; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Functional comparison of transactivation by human retrovirus rev and rex genes.

Authors:  H Sakai; H Siomi; H Shida; R Shibata; T Kiyomasu; A Adachi
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

8.  DNA transfection of mouse lymphoid cells by the combination of DEAE-dextran-mediated DNA uptake and osmotic shock procedure.

Authors:  T Takai; H Ohmori
Journal:  Biochim Biophys Acta       Date:  1990-01-30

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  84 in total

1.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

5.  Functional analysis of vif genes derived from various primate immunodeficiency viruses.

Authors:  Y Yamamoto; Y Saito; S Iida; J Asano; S Sone; A Adachi
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

6.  Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.

Authors:  Jared R Auclair; Karin M Green; Shivender Shandilya; James E Evans; Mohan Somasundaran; Celia A Schiffer
Journal:  Proteins       Date:  2007-11-01

Review 7.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

8.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells.

Authors:  Naomi Tsurutani; Jiro Yasuda; Naoki Yamamoto; Byung-Il Choi; Motohiko Kadoki; Yoichiro Iwakura
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

Authors:  X Y Ma; P Sova; W Chao; D J Volsky
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.